© China Lung Oncology Group and Wiley Publishing Asia Pty Ltd
All articles accepted from 25 November 2014 are published under the terms of the Creative Commons License as stated in the final article. Articles accepted before this date were published under the agreement as stated in the final article.
Edited By: Qinghua Zhou and Yan Sun
Impact Factor: 0.898
ISI Journal Citation Reports © Ranking: 2014: 53/57 (Respiratory System); 193/211 (Oncology)
Online ISSN: 1759-7714
Recently Published Issues
Read the NEW Virtual Issue on EBUS and Lung Cancer FREE online
EBUS has been widely used in the diagnosis/staging of lung cancer. In this special issue, some well-known interventional pulmonologists presented their cutting-edge knowledge in Thoracic Cancer, focusing on EBUS in the diagnosis/staging of lung cancer.
Most acccessed articles
Most Accessed articles published in 2012-2013
Management of malignant pleural effusion: Options and recommended approaches
Clinical and biologic prognostic factors in malignant pleural mesothelioma
Lung cancer incidence and mortality in China, 2009
Incidence and mortality of breast cancer in China, 2008
Diagnostic value of autofluorescence bronchoscopy in lung cancer
Thoracic Cancer will become an open access journal from January 2015. Manuscripts submitted after 25 November 2014 and accepted for publication will be published as open access articles, immediately free to read, download and share. Authors or their funder will be required to pay an Article Publication Charge upon acceptance.
Increased Impact Factor 1.126 !
Read, cite the journal, or submit your paper to keep contributing to the success of Thoracic Cancer.
The only English language and international lung cancer journal from Asia-Pacific!
Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, and other thoracic malignancies.
Call for Papers
Review articles - Free Online
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer